---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-135478"
form_type: "8-K"
ticker: "SLNO"
cik: "0001484565"
company_name: "SOLENO THERAPEUTICS INC"
filed_at: "2024-05-10T23:59:59+00:00"
generated_at: "2026-06-02T03:33:47.324261+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Soleno Q1 net loss $21.4M; FDA breakthrough therapy for DCCR; NDA mid-2024

## Summary
- Net loss of $21.4M ($0.59 per share) vs $8.4M loss in Q1 2023; R&D expense rose to $14.6M from $5.3M.
- Pro forma cash reserves $307.2M after May 2024 public offering netting $148.8M.
- FDA granted Breakthrough Therapy Designation for DCCR in Prader-Willi syndrome; NDA submission on track for mid-2024.
- Strengthened leadership: appointed Chief Commercial Officer, VP Europe, VP Human Resources.
- Contingent consideration liability for DCCR commercial milestones valued at $12.0M.

## SEC filing metadata
- accession: 0001193125-24-135478
- form_type: 8-K
- ticker: SLNO
- cik: 0001484565
- company_name: SOLENO THERAPEUTICS INC
- filed_at: 2024-05-10T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1484565/000119312524135478/0001193125-24-135478-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1484565/000119312524135478/d767565d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-135478
- JSON: https://secwatch.observer/filing/0001193125-24-135478.json
- Plain text: https://secwatch.observer/filing/0001193125-24-135478.txt

## Key facts
- Earnings Releases
  SOLENO THERAPEUTICS INC reported first quarter ended March 31, 2024 results: net income Net loss was approximately $21.4 million, or $0.59 per basic and diluted share, EPS $0.59 per basic and diluted share.
  - Period: first quarter ended March 31, 2024
  - Net income: Net loss was approximately $21.4 million, or $0.59 per basic and diluted share
  - EPS: $0.59 per basic and diluted share
  - Result: reported results
  source text: Net loss was approximately $21.4 million, or $0.59 per basic and diluted share, for the quarter ended March 31, 2024
  evidence_url: https://www.sec.gov/Archives/edgar/data/1484565/000119312524135478/0001193125-24-135478-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.